A meaningful portion of Merck’s MRK revenues comes from its oncology franchise anchored by its blockbuster PD-L1 inhibitor, ...

Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...

US pharma major Merck & Co is trying to make its looming Keytruda (pembrolizumab) patent hill look more like a speed bump.

MSD awaits 20 potential launches and 80 late-stage readouts across its pipeline, which it believes will double $35bn ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of KANDLELIT-007, a ...

Rising clinical innovations, combination therapy advances, and growing cancer prevalence accelerate global and U.S. market growth.Austin, Texas, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Keytruda Market Size ...

The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.

Wolfe is bullish on Merck & Company Inc (NYSE:MRK) while stepping back from AbbVie Inc (NYSE:ABBV). Analysts say the market is underestimating Merck’s ability to grow beyond Keytruda and has already ...

First pivotal Phase 3 trial to show superiority of KEYTRUDA plus a TROP2 antibody-drug conjugate, Trodelvy, versus standard of care in first-line metastatic TNBC “These results have the potential to ...

RAHWAY, N.J., December 17, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-B15 trial ...

KEYTRUDA monotherapy now approved as neoadjuvant treatment, continued as adjuvant treatment combined with radiotherapy with or without concomitant cisplatin then as monotherapy Based on results of ...

At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...